<DOC>
	<DOCNO>NCT00925002</DOCNO>
	<brief_summary>This Phase 3 , open-label study design obtain additional , long-term , open-label safety efficacy data Fx-1006A continue provide patient 20 mg oral Fx-1006A ( soft gel capsule ) complete either Protocol Fx-006 ( 1 year , open-label extension study Protocol Fx-005 randomize , double-blind , placebo-controlled , 18-month study evaluate safety efficacy Fx-1006A ) Protocol Fx1A-201 ( Phase 2 , open-label study evaluate TTR stabilization well safety tolerability Fx-1006A ) market availability Fx-1006A individual patient ' country residence . Patients successfully complete Protocol Fx-006 Fx1A-201 report clinical unit Day 0 ( Baseline ) sign inform consent form determine eligibility Protocol Fx1A-303 . In addition , Day 0 ( Baseline ) , patient entrance criterion review medical history demography patient obtain . The relevant end study assessment Protocols Fx1A-201 Fx-006 serve Baseline assessments Protocol Fx1A-303 examination perform within 30 day Day 0 ( Baseline ) . For patient successfully complete Protocol Fx-006 , Karnofsky Performance Scale Index assess cranial nerve upper limb component NIS perform combined NIS-LL data end study visit Protocol Fx-006 . If 30 day final study visit Fx-006 Fx1A-201 Day 0 ( Baseline ) Fx1A-303 , Day 0 study procedure perform ( i.e. , data final study visit previous study utilize ) . Eligible patient begin once-daily dose 20 mg Fx-1006A home Day 1 ( i.e. , first dose ) return clinical unit study visit every 6 month . Adverse event ( AEs ) concomitant medication use collect 6-month visit clinical unit , female , urine pregnancy test perform . An abbreviated physical examination ( include weight vitals sign ) conduct every 6 month visit . A telephone call make 3-month interval clinic visit assess safety use concomitant medication . For evaluation efficacy , NIS , Norfolk QOL-DN , Karnofsky Performance Scale Index perform annual basis ( i.e. , every 6-month visit ) . An end study visit occur upon patient withdrawal ( reason ) , program discontinuation Sponsor , upon market availability Fx-1006A individual patient ' country residence .</brief_summary>
	<brief_title>Safety And Efficacy Evaluation Of Fx-1006A In Subjects With Transthyretin Amyloidosis</brief_title>
	<detailed_description />
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>Patient successfully complete either Protocol Fx006 Fx1A201 . If female , patient postmenopausal , surgically sterilize , willing use two acceptable method birth control ( i.e. , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide ) throughout study 3 month end study . ( A condom alone consider acceptable method birth control . ) Patient , opinion investigator , willing able comply investigational product regimen study requirement . Patient successfully complete either Protocol Fx006 Fx1A201 . Chronic use nonprotocol approve nonsteroidal antiinflammatory drug ( NSAIDs ) , define great 3 4 times/month . The following NSAIDs allow : acetylsalicylic acid , etodolac , ibuprofen , indomethicin , ketoprofen , nabumetone , naproxen , nimesulide , piroxicam , sulindac . If female , patient pregnant breast feeding . Clinically significant medical condition , opinion investigator , would place patient increase risk participate study . The patient receive liver heart transplant prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>